Stoke Therapeutics
Price & Volume
Stats
See moreOpen | $24.66 |
Previous Close | $24.73 |
Day Range | $23.37-$24.94 |
52W Range | $5.35-$24.80 |
Market Cap | $1.3B |
Shares Short | 11M |
Financials
See moreRevenue (12 Mos) | $199.8M |
Revenue Growth (YoY) | 186% |
Gross Profit (12 Mos) | $199.8M |
Diluted EPS | $0.89 |
News
See moreYahoo Finance • 16 days ago
7 Biotech Stocks Trading At 52-Week Highs - Can The Rally Continue?
Yahoo Finance • 28 days ago
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
Yahoo Finance • last month
Stoke Therapeutics stock hits 52-week high at $18.61
Yahoo Finance • 2 months ago
Biogen, Stoke Therapeutics Dose First Patient in Phase 3 Trial of Zorevunersen for Dravet Syndrome
About
CEO | Mr. Ian F. Smith A.C.A., C.P.A. |
Address | 45 Wiggins Avenue, Bedford, MA, United States, 01730 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 128 |
